Drawing for CELYAD

USPTO serial 79186151

CELYAD

Reviewed by CopyMark Law Group

Reg. 5158439Status 706Renewal
Filing date
Status date
Registration date
Mar 14, 2017
Examiner
MAYER, DAVID COREY
Law office
GENERIC WEB UPDATE

What this means

This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.

Need help with CELYAD?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $1,097*

Plus Government fees of $1,950

Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Todd A. Denys

Todd A. Denys PORZIO BROMBERG & NEWMAN, P.C.100 Southgate ParkwayMorristown, NJ 07962UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
005[ Cellular pharmaceutical preparations for medical use for oncology and cardio-vascular disease treatment; Surgical implants being cellular pharmaceutical preparations comprising living tissue; Cellular pharmaceutical preparations for medical use for the treatment of tumors and cardio-vascular diseases ]ACTIVE—
010[ Surgical and medical instruments for use in the diagnosis and treatment of oncology and cardio-vascular diseases; Catheters; Medical devices being surgical implants comprising natural, non-living materials ]ACTIVE—
042Scientific and technological services, namely, scientific research, analysis and testing in the field of oncology and cardio-vascular diseases; Research services in the field of cell therapy and medical and surgical instrumentACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Mar 14, 2026REM4COURTESY REMINDER - SEC. 71 (10-YR) E-MAILED—
Nov 21, 2025NREPNEW REPRESENTATIVE AT IB RECEIVED—
Sep 4, 2025RNWLINTERNATIONAL REGISTRATION RENEWED—
May 9, 2025INNPPARTIAL INVALIDATION PROCESSED BY THE IB—
Mar 15, 2025XXSSGENERIC MADRID TRANSACTION SENT TO IB—
Mar 15, 2025XXCRGENERIC MADRID TRANSACTION CREATED—
Mar 13, 2025NREPNEW REPRESENTATIVE AT IB RECEIVED—
Dec 31, 2024INPRPARTIAL INVALIDATION OF REG EXT PROTECTION CREATED—
Apr 30, 2024NA71NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED—
Apr 30, 202471AGREGISTERED-SEC.71 ACCEPTED—
Apr 23, 2024APRECASE ASSIGNED TO POST REGISTRATION PARALEGAL—
Aug 31, 2023ES71TEAS SECTION 71 RECEIVED—
Mar 14, 2022REM3COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED—
Mar 20, 2021NREPNEW REPRESENTATIVE AT IB RECEIVED—
Nov 7, 2020ADCHCHANGE OF NAME/ADDRESS REC'D FROM IB—
Jun 6, 2019NREPNEW REPRESENTATIVE AT IB RECEIVED—
Jul 8, 2017FINOFINAL DECISION TRANSACTION PROCESSED BY IB—
Jun 17, 2017FICSFINAL DISPOSITION NOTICE SENT TO IB—
Jun 16, 2017FIMPFINAL DISPOSITION PROCESSED—
Jun 14, 2017FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB—
Mar 14, 2017R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Dec 27, 2016NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Dec 27, 2016PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Dec 23, 2016GPNXNOTIFICATION PROCESSED BY IB—
Dec 7, 2016OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB—
Dec 7, 2016OP2RNOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB—
Dec 7, 2016NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Nov 19, 2016PREVLAW OFFICE PUBLICATION REVIEW COMPLETED—
Nov 18, 2016CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Nov 16, 2016XAECEXAMINER'S AMENDMENT ENTERED—
Nov 16, 2016GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Nov 16, 2016GNEAEXAMINERS AMENDMENT E-MAILED—
Nov 16, 2016CNEAEXAMINERS AMENDMENT -WRITTEN—
Nov 8, 2016TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Nov 8, 2016CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Nov 7, 2016ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Nov 7, 2016REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Nov 7, 2016ALIEASSIGNED TO LIE—
Oct 27, 2016NREVNOTICE OF REVIVAL - MAILED—
Oct 27, 2016TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Oct 27, 2016PETGPETITION TO REVIVE-GRANTED—
Oct 27, 2016PROATEAS PETITION TO REVIVE RECEIVED—
May 14, 2016RFNTREFUSAL PROCESSED BY IB—
Apr 26, 2016MAFRAPPLICATION FILING RECEIPT MAILED—
Apr 25, 2016RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
Apr 25, 2016RFRRREFUSAL PROCESSED BY MPU—
Apr 23, 2016RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Apr 22, 2016CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Apr 22, 2016DOCKASSIGNED TO EXAMINER—
Apr 22, 2016NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Apr 21, 2016REPRSN ASSIGNED FOR SECT 66A APPL FROM IB—

Frequently asked questions

Related guidance